MedTrace Logo

Proton Pump Inhibitor Preventing Upper Gastrointestinal Injury In Patients On Dual Antiplatelet Therapy After CABG

NCT03908593 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 232

Last updated 2023-08-18

No results posted yet for this study

Summary

The purpose of this study is to compare the efficacy and safety for 12- vs. 1-month of pantoprazole treatment in preventing dual antiplatelet therapy (DAPT)-related upper gastrointestinal mucosal injury after coronary artery bypass grafting (CABG).

To date, there has been no study using esophagogastroduodenoscopy (EGD) to compare the differences in upper gastrointestinal mucosal injury (including reflux esophagitis) after 6 and 12 months of PPI treatment combined with two different DAPT regimens (clopidogrel plus aspirin or ticagrelor plus aspirin).

Conditions

  • Gastrointestinal Ulcer (Peptic) or Erosion
  • Anti-Platelet Therapy
  • Coronary Artery Bypass

Interventions

DRUG

Pantoprazole

Pantoprazole (40mg qd) will be concomitant used with DAPT

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Lifen Yu, MD, Ph.D · Department of Gastroenterology, Ruijin Hospital

  • Qiang Zhao, MD, Ph.D · Department of Cardiovascular Surgery, Ruijin Hospital

  • Yunpeng Zhu, MD · Department of Cardiovascular Surgery, Ruijin Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-14
Primary Completion
2023-12-30
Completion
2024-01-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03908593 on ClinicalTrials.gov